Description：ELISA for the detection of Talquetamab in human serum and plasma.
Lead time for this kit is 5 weeks.
About the kit： - Uses anti-idiotypic monoclonal antibodies sourced from our vendor partner in the US, which ensures higher specificity, and low cross reactivity.
- Recovery rates are between 85 - 115％ - Validated as per US FDA guidelines for Bioassays - Developed using the innovator drug as calibrator - Shelf life： 1 year.Talquetamab is an investigational, off-the-shelf, T-cell redirecting bispecific antibody, targeting the novel biomarker GPRC5D on multiple myeloma cells and CD3 on T-cells.
The FDA has granted breakthrough therapy designation to talquetamab for the treatment of adult patients with relapsed or refractory multiple myeloma in June 2022.
仕様
サイズ：1 x 96 wells
Reactivity：Human
アプリケーション：ELISA,Immunoassay
Sensitivity：Please refer to the current IFU for the updated calibrator range and sensitivity.
